US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Apnimed Inc. (APMD): Apnimed Awakens: Wild IPO Ride Ends with 56% First-Day Gain

Apnimed Inc. (APMD): Sleep-Related Biopharma in Phase 3 Sets Terms for IPO

Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.</li>
<li>Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.</li>
<li>IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.</li>
</ul>


Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.
Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.
IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.


Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story